| In this podcast episode, 3 experts answers questions on the management of hemophilia A from a live webinar. Topics include: * Which patients should have pharmacokinetic-guided therapy? * Toxicities with PEGylated extended half-life products * Factor VIII and bone health * Factor VIII peaks, thrombotic risk, and cardiovascular disease * Choosing between extended half-life products and emicizumab for active patients * Role of fitusiran in the treatment paradigm if approved

Presenters:Miguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasMark Reding, MDProfessor of MedicineDivision of Hematology, Oncology, and TransplantationDirectorCenter for Bleeding and Clotting DisordersUniversity of MinnesotaMinneapolis, MinnesotaGuy A. Young, MDProfessor of PediatricsDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesUniversity of Southern California Keck School of MedicineLos Angeles, California |

Link to full program, including downloadable slidesets, expert commentary, and on-demand webcast:
https://bit.ly/3zZwP6G